Neoplastic meningitis-related prognostic significance of the Karnofsky performance status

Marc C. Chamberlain, Sandra K. Johnston, Michael Glantz

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: The prognostic significance of Karnofsky performance status in neoplastic meningitis (NM) has not been demonstrated in patient groups similarly matched for known prognostic variables. Objective: To determine the effect of performance status on survival in NM. Design: Retrospective comparison. Setting: A university tertiary medical center. Patients: Two well-matched cohorts with cytologically positive NM with (n=30; group A) and without (n=30; group B) independence in activities of daily living as defined by a Karnofsky performance status score of 70 or greater or less than 70, respectively. Main Outcome Measures: Groups were matched on age, primary tumor, site of NM disease (cranial nerves or spinal cord), treatment (radiotherapy and chemotherapy; systemic and intraventricular), and absence of cerebrospinal fluid compartmentalization, NM-related encephalopathy, and neuroradiographic bulky central nervous system disease. Primary tumor histologic diagnoses included breast cancer (20 patients), non-Hodgkin lymphoma (10 patients), lung cancer (10 patients), melanoma (8 patients), and others (12 patients). At presentation, NM revealed cranial neuropathy (30 patients) or spinal cord dysfunction (39 patients). Radiotherapy was administered to 49 patients (whole brain only in 12 patients; restricted spine only in 35; whole brain and restricted spine in 2). All the patients received intraventricular chemotherapy, and 49 received concurrent tumor-specific systemic chemotherapy. Results: Median survival was 6 weeks (range, 3-10 weeks) in group B compared with 15.5 weeks (range, 8-58 weeks) in group A (P < .001). No treatment-related deaths were observed. All the patients demonstrated progressive disease and died of either NM or systemic cancer. Conclusions: A low Karnofsky performance status score predicts poor survival in patients with NM. Patients with a low Karnofsky performance status score may be best served by offering supportive care.

Original languageEnglish (US)
Pages (from-to)74-78
Number of pages5
JournalArchives of Neurology
Volume66
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Karnofsky Performance Status
Meningitis
Cranial Nerve Diseases
Drug Therapy
Survival
Neoplasms
Spinal Cord
Spine
Research Design
Radiotherapy
Central Nervous System Diseases
Brain
Brain Diseases
Activities of Daily Living

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Chamberlain, Marc C. ; Johnston, Sandra K. ; Glantz, Michael. / Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. In: Archives of Neurology. 2009 ; Vol. 66, No. 1. pp. 74-78.
@article{5a8d44e6a07f4fae951e4949c5742bd3,
title = "Neoplastic meningitis-related prognostic significance of the Karnofsky performance status",
abstract = "Background: The prognostic significance of Karnofsky performance status in neoplastic meningitis (NM) has not been demonstrated in patient groups similarly matched for known prognostic variables. Objective: To determine the effect of performance status on survival in NM. Design: Retrospective comparison. Setting: A university tertiary medical center. Patients: Two well-matched cohorts with cytologically positive NM with (n=30; group A) and without (n=30; group B) independence in activities of daily living as defined by a Karnofsky performance status score of 70 or greater or less than 70, respectively. Main Outcome Measures: Groups were matched on age, primary tumor, site of NM disease (cranial nerves or spinal cord), treatment (radiotherapy and chemotherapy; systemic and intraventricular), and absence of cerebrospinal fluid compartmentalization, NM-related encephalopathy, and neuroradiographic bulky central nervous system disease. Primary tumor histologic diagnoses included breast cancer (20 patients), non-Hodgkin lymphoma (10 patients), lung cancer (10 patients), melanoma (8 patients), and others (12 patients). At presentation, NM revealed cranial neuropathy (30 patients) or spinal cord dysfunction (39 patients). Radiotherapy was administered to 49 patients (whole brain only in 12 patients; restricted spine only in 35; whole brain and restricted spine in 2). All the patients received intraventricular chemotherapy, and 49 received concurrent tumor-specific systemic chemotherapy. Results: Median survival was 6 weeks (range, 3-10 weeks) in group B compared with 15.5 weeks (range, 8-58 weeks) in group A (P < .001). No treatment-related deaths were observed. All the patients demonstrated progressive disease and died of either NM or systemic cancer. Conclusions: A low Karnofsky performance status score predicts poor survival in patients with NM. Patients with a low Karnofsky performance status score may be best served by offering supportive care.",
author = "Chamberlain, {Marc C.} and Johnston, {Sandra K.} and Michael Glantz",
year = "2009",
month = "1",
doi = "10.1001/archneurol.2008.506",
language = "English (US)",
volume = "66",
pages = "74--78",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "1",

}

Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. / Chamberlain, Marc C.; Johnston, Sandra K.; Glantz, Michael.

In: Archives of Neurology, Vol. 66, No. 1, 01.2009, p. 74-78.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neoplastic meningitis-related prognostic significance of the Karnofsky performance status

AU - Chamberlain, Marc C.

AU - Johnston, Sandra K.

AU - Glantz, Michael

PY - 2009/1

Y1 - 2009/1

N2 - Background: The prognostic significance of Karnofsky performance status in neoplastic meningitis (NM) has not been demonstrated in patient groups similarly matched for known prognostic variables. Objective: To determine the effect of performance status on survival in NM. Design: Retrospective comparison. Setting: A university tertiary medical center. Patients: Two well-matched cohorts with cytologically positive NM with (n=30; group A) and without (n=30; group B) independence in activities of daily living as defined by a Karnofsky performance status score of 70 or greater or less than 70, respectively. Main Outcome Measures: Groups were matched on age, primary tumor, site of NM disease (cranial nerves or spinal cord), treatment (radiotherapy and chemotherapy; systemic and intraventricular), and absence of cerebrospinal fluid compartmentalization, NM-related encephalopathy, and neuroradiographic bulky central nervous system disease. Primary tumor histologic diagnoses included breast cancer (20 patients), non-Hodgkin lymphoma (10 patients), lung cancer (10 patients), melanoma (8 patients), and others (12 patients). At presentation, NM revealed cranial neuropathy (30 patients) or spinal cord dysfunction (39 patients). Radiotherapy was administered to 49 patients (whole brain only in 12 patients; restricted spine only in 35; whole brain and restricted spine in 2). All the patients received intraventricular chemotherapy, and 49 received concurrent tumor-specific systemic chemotherapy. Results: Median survival was 6 weeks (range, 3-10 weeks) in group B compared with 15.5 weeks (range, 8-58 weeks) in group A (P < .001). No treatment-related deaths were observed. All the patients demonstrated progressive disease and died of either NM or systemic cancer. Conclusions: A low Karnofsky performance status score predicts poor survival in patients with NM. Patients with a low Karnofsky performance status score may be best served by offering supportive care.

AB - Background: The prognostic significance of Karnofsky performance status in neoplastic meningitis (NM) has not been demonstrated in patient groups similarly matched for known prognostic variables. Objective: To determine the effect of performance status on survival in NM. Design: Retrospective comparison. Setting: A university tertiary medical center. Patients: Two well-matched cohorts with cytologically positive NM with (n=30; group A) and without (n=30; group B) independence in activities of daily living as defined by a Karnofsky performance status score of 70 or greater or less than 70, respectively. Main Outcome Measures: Groups were matched on age, primary tumor, site of NM disease (cranial nerves or spinal cord), treatment (radiotherapy and chemotherapy; systemic and intraventricular), and absence of cerebrospinal fluid compartmentalization, NM-related encephalopathy, and neuroradiographic bulky central nervous system disease. Primary tumor histologic diagnoses included breast cancer (20 patients), non-Hodgkin lymphoma (10 patients), lung cancer (10 patients), melanoma (8 patients), and others (12 patients). At presentation, NM revealed cranial neuropathy (30 patients) or spinal cord dysfunction (39 patients). Radiotherapy was administered to 49 patients (whole brain only in 12 patients; restricted spine only in 35; whole brain and restricted spine in 2). All the patients received intraventricular chemotherapy, and 49 received concurrent tumor-specific systemic chemotherapy. Results: Median survival was 6 weeks (range, 3-10 weeks) in group B compared with 15.5 weeks (range, 8-58 weeks) in group A (P < .001). No treatment-related deaths were observed. All the patients demonstrated progressive disease and died of either NM or systemic cancer. Conclusions: A low Karnofsky performance status score predicts poor survival in patients with NM. Patients with a low Karnofsky performance status score may be best served by offering supportive care.

UR - http://www.scopus.com/inward/record.url?scp=58449127597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449127597&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2008.506

DO - 10.1001/archneurol.2008.506

M3 - Article

VL - 66

SP - 74

EP - 78

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 1

ER -